Hormonal
Emerging weight-lowering drugs (GLP-1/GIP/Glucagon agonists, amylin analogues, activin receptor antagonists) reduce cardiovascular risk factors (blood pressure, lipids, inflammation) and major adverse cardiovascular events (MACE) in obese patients, with some effects being independent of weight loss.
If you are obese and have cardiovascular risk factors, emerging drugs like semaglutide and tirzepatide offer significant benefits beyond just weight loss, including reduced risk of heart attacks and strokes. These benefits may come from direct effects on blood vessels and inflammation, not just weight loss. While side effects like nausea are common, they can often be managed. Oral options are becoming available, reducing the need for injections. These drugs are most effective when combined with lifestyle changes, but they can provide substantial help where lifestyle alone has failed.
The positive cardiovascular effects of GLP1-RAs and dual agonists GLP1-GIP are probably related to combined weight loss, lowered BP and improved glucometabolic profile... The SELECT trial indeed showed a 20% reduction in MACE in subjects treated with semaglutide compared to placebo... these changes were independent from weight loss, suggesting a disease-modifying effect not related to weight reduction
Why this rating
Supported by multiple RCTs (SELECT, SURPASS, Phase 2/3 trials) and meta-analyses, though some newer drugs lack long-term MACE data.
Source
Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review
Alessandro Ciarloni et al. · Biomedicines · 2026
DOI 10.3390/biomedicines14040778
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →